The period of 2017 and 2018 has realized a significant uptick in our CRO services business focused on diseased and normal human cell platform technology creation and in the use of diseased and normal human cells in bioassays profiling the lead therapeutic assets of industry and academic clients.
“We thank very much the many clients that have made use of our diseased and normal human cell platform technology and that have entrusted us to perform bioassay profiling on lead therapeutic assets,” said Dr. Erik Schwiebert. “Moreover, this blossoming of this sector of our business correlates with the presence of DBM’s Head of Business Development, Dr. Matthew Redmann. He has been creative and tireless in targeting and identifying new clients.”
DBM is under confidentiality agreement with the majority of its clients. But in the US, DBM has multiple clients and partners in the Boston area and San Francisco Bay Area, as well as in the San Diego and Los Angeles areas. We also have numerous clients in the Philadelphia area. In addition, we have smaller clients in Kentucky and Tennessee. Overseas, we have clients and partners in the UK, Scotland, France, Italy, and in Japan, and we are currently negotiating with additional clients in Canada, Germany and Sweden. DBM only has a single client that has a partial presence in Alabama, despite being headquartered in Birmingham. The clients include and range from multi-billion-dollar BioPharmaceutical companies and companies that operate in other sectors to small Biotechnology companies. “We endeavor to treat every client the same, with a communicative, collaborative and customized approach,” explained Dr. Matt Redmann, DBM’s Head of Business Development.
In these more vigorous efforts, DBM realized a niche in specialty cell culture and engineering and in unique human cell-based bioassays that leverages “Diseased and Normal Human Cell Platform Technologies” and we offer such expertise in the Renal, Metabolic, Respiratory and Dermatology spaces. We also wish to recognize specifically our relationship with the Monell Chemical Senses Center in Philadelphia where we are collaborating to develop human taste bud epithelial cell platforms for biotechnology applications, including a funded effort supported by the Bill and Melinda Gates Foundation. Under the Metabolic umbrella in our CRO services sector, the marketplaces for taste and smell, research foci for The Monell Center, are unprecedented and rival that of BioPharmaceutical marketplaces.
All of the above fits with our core principle that “human cells of physiological and disease relevance are the key ingredient to everything that DBM does within its own R&D programs and its CRO services.” In lay terms, if one is endeavoring to give a discovered drug or product to a human patient or consumer in the end, why not do the experiments on human cells of relevance.” DBM will continue to support and promote this idea of immense value.